X4 Pharmaceuticals, Inc (XFOR): Free Cash Flow
-$85.62M
Year ended 2025-12-31
| Period ended | Free Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$85.62M | n/m | 2026-03-17, From 2025-01-01 |
| 2024-12-31 | -$131.23M | n/m | 2026-03-17, From 2024-01-01 |
| 2023-12-31 | -$96.57M | n/m | 2026-03-17, From 2023-01-01 |
| 2022-12-31 | -$77.20M | n/m | 2025-03-26, From 2022-01-01 |
| 2021-12-31 | -$71.52M | n/m | 2024-03-21, From 2021-01-01 |
| 2020-12-31 | -$60.18M | n/m | 2023-03-21, From 2020-01-01 |
| 2019-12-31 | -$48.23M | n/m | 2022-03-17, From 2019-01-01 |
| 2018-12-31 | -$25.42M | n/m | 2021-03-19, From 2018-01-01 |
| 2017-12-31 | -$21.69M | n/c | 2020-03-12, From 2017-01-01 |
| 2016-12-31 | -$21.71M | n/a | 2019-03-11, From 2016-01-01 |
Free Cash Flow at similar companies
| Company | Year ended | Free Cash Flow | Change YoY |
|---|---|---|---|
| X4 Pharmaceuticals, Inc (XFOR) | 2025-12-31 | -$85.62M | n/m |
| C4 Therapeutics, Inc. (CCCC) | 2025-12-31 | -$99.30M | n/m |
| Precision Biosciences Inc (DTIL) | 2025-12-31 | -$65.93M | n/m |
| Kymera Therapeutics, Inc. (KYMR) | 2025-12-31 | -$234.34M | n/m |
| Sangamo Therapeutics, Inc (SGMOQ) | 2025-12-31 | -$97.31M | n/m |
| Voyager Therapeutics, Inc. (VYGR) | 2025-12-31 | -$135.06M | n/m |
| Editas Medicine, Inc. (EDIT) | 2025-12-31 | -$165.85M | n/m |
| Scilex Holding Co (SCLX) | 2025-12-31 | $3.68M | -81.0% |
| Metagenomi Therapeutics, Inc. (MGX) | 2025-12-31 | -$89.47M | n/m |
Compare XFOR, CCCC, DTIL, KYMR side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗